Y
Yanhong Tai
Publications - 3
Citations - 6850
Yanhong Tai is an academic researcher. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 1, co-authored 1 publications receiving 5215 citations.
Papers
More filters
Journal ArticleDOI
Pathological findings of COVID-19 associated with acute respiratory distress syndrome.
Zhe Xu,Lei Shi,Yijin Wang,Ji-Yuan Zhang,Lei Huang,Chao Zhang,Shuhong Liu,Peng Zhao,Hongxia Liu,Li Zhu,Yanhong Tai,Changqing Bai,Tingting Gao,Jin-Wen Song,Peng Xia,Jing-Hui Dong,Jingmin Zhao,Fu-Sheng Wang +17 more
TL;DR: O surto do novo coronavÃrus (COVID-19) em Wuhan, China, iniciado em dezembro de 2019, evoluiu para se tornar uma pandemia global A.
Journal ArticleDOI
36P Prevalence, clinical characteristics, and treatment outcomes of patients with BRAF-mutated advanced NSCLC in China: A real-world multi-center study
B Jia,Ji Zhao,Bangming Jin,F Zhang,S. Wang,Li Zhang,Z. Wang,Tongtong An,Y P Wang,Minglei Zhuo,J.W. Li,X. Yang,S.J. Li,H Chen,Yujia Chi,J. Wang,Xinbo Zhai,Yanhong Tai,Yu Liu,G.Y. Guan +19 more
Journal ArticleDOI
135P Camrelizumab plus chemotherapy as first-line therapy for NSCLC: A pooled analysis of two randomized phase III trials with extended follow-up
C. Zhou,G. F. Chen,Yu Huang,J. Chen,Y. Cheng,Q. Wang,J. Zhou,J. Shi,X Xu,Li Lin,W Zhang,Y. Zhang,Y. Liu,J. G. Feng,Z Wang,Yanhong Tai,X. Ma,X.X. Lu +17 more
TL;DR: The phase 3 CameL and CameL-sq studies have proven the superiority of first-line camrelizumab plus chemotherapy (camre-chemo) vs chemo for progression-free survival (PFS) in patients with advanced non-squamous and squamous NSCLC, respectively as discussed by the authors .